Recruiting

Observational Study

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07807943

Conditions

Observational Study

Geniculate Artery

Embolization

Symptomatic Knee Osteoarthritis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

SOC (Standard of care)

Study Details

Brief summary:

To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample >10-year survivors.

Conditions

Observational Study

Geniculate Artery

Embolization

Symptomatic Knee Osteoarthritis

Study ID

NCT07807943

Start date

Aug 26, 2026

Status verified date

Sep, 2026

Completion date

Jun 30, 2030

Anticipated

Primary completion date

May 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria

1. Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy
2. Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment
3. Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications
4. Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference
5. Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center

Exclusion Criteria

  • Active joint infection or suspected septic arthritis
  • Life expectancy <6 months
  • Prior knee arthroplasty in the index knee
  • Coagulopathy or contraindications to angiography
  • GFR <30 mL/min/1.73m²
  • Peripheral artery disease with stenosis or occlusion of lower extremity vasculature (relative contraindication per SIR standards, given geniculate artery collateral perfusion role)
  • Radiographically normal knee joint (KL grade 0-1) - alternative etiologies should be sought
  • Known active autoimmune/inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis)
  • Any medical condition or clinical abnormality that, per investigator judgment, precludes safe participation in and completion of the study

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Interventions

SOC (Standard of care)

Patients scheduled for standard of care

Primary outcome measure

  • Numeric Rating Scale Questionnaire [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts and Locations

Central contacts

Locations

UT MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77044

Contacts

Principal Investigator:

Cardenas J Nicolas, MD

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Sep 8, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-09-08.